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Abstract 
Background 
Human papillomavirus (HPV) vaccination for young women up to age 26 is highly cost-effective 
and has been implemented in 65 countries globally. We investigate the cost-effectiveness for 
HPV vaccination program in older women (age >26 years), heterosexual men and men who have 
sex with men (MSM). 
Method 
A targeted literature review was conducted on PubMed for publications between January 2000 
and January 2017 according to the PRISMA guidelines. We included English-language articles 
that reported the incremental cost-effectiveness ratio (ICER) of HPV vaccination programs for 
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women over age 26, heterosexual men, and MSM and identified the underlying factors for its 
cost-effectiveness. 
Results 
We included 36 relevant articles (six, 26 and four in older women, heterosexual men and MSM, 
respectively) from 17 countries (12 high-income (HICs) and five low- and middle-income 
(LMICs) countries). Most (4/6) studies in women over age 26 did not show cost-effectiveness 
($65,000-192,000/QALY gained). Two showed cost-effectiveness, but only when the vaccine 
cost was largely subsidised and protection to non-naïve women was also considered. Sixteen of 
26 studies in heterosexual men were cost-effective (ICER=$19,600-52,800/QALY gained in 
HICs; $49-5,860/QALY gained in LMICs). Nonavalent vaccines, a low vaccine price, fewer 
required doses, and a long vaccine protection period were key drivers for cost-effectiveness. In 
contrast, all four studies on MSM consistently reported cost-effectiveness (ICER=$15,000-
$43,000/QALY gained), particularly in MSM age <40 years and those who were HIV-positive. 
Countries’ vaccination coverage did not significantly correlate with its per-capita Gross National 
Income. 
Conclusion 
Targeted HPV vaccination for MSM should be next priority in HPV prevention after having 
established a solid girls vaccination programme. Vaccination for heterosexual men should be 
considered when 2-dose 4vHPV/9vHPV vaccines become available with a reduced price, 
whereas targeted vaccination for women over age 26 is unlikely to be cost-effective. 
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Introduction 
Human Papillomavirus (HPV) infection is a common sexually transmitted infection (STI) and a 
necessary cause for cervical cancer in women [1]. It is also responsible for anal, vaginal, vulvar, 
oropharyngeal and penile cancers [2]. Cervical cancer was the fourth most common cancer 
among women globally, and second (only after breast cancer) in women in low- and middle- 
income countries (LMICs) [3]. According to the World Health Organization (WHO), an 
estimated 530,000 cervical cancers were diagnosed in 2012, and approximately 270,000 women 
per year died from cervical cancer worldwide. More than 90% of deaths occur in low- and 
middle- income countries (LMICs) due to poor access to screening and treatment services [4]. 
However, HPV infection is vaccine-preventable, and currently approved vaccines have achieved 
an excellent safety and efficacy profile [5]. 
National HPV vaccination programs have been initiated over a decade ago, but there are large 
disparities in coverage and targeted populations of vaccination strategies between countries 
where the program has been introduced. By mid-2016, national HPV vaccination programs have 
been established in 65 countries globally, most of which are high-income countries (HICs). 
Strong momentum has been observed to expand HPV vaccination programs to LMICs, where the 
majority of HPV-related cancers occur [6]. 
The type of HPV vaccination program that countries choose to implement depends on the 
countries’ economic status, disease priorities, and the cost-effectiveness of the programs. Most 
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HPV vaccination programs target 9-14 year old schoolgirls before sexual debut and it is cost-
effective if more than 70% of young women are vaccinated [7]. There remain lots of debate 
around whether it is cost-effective to expand the existing vaccination programs to also include 
women older than 26 years, heterosexual men, and men who have sex with men (MSM). Unlike 
HPV vaccination for adolescent girls and women up to 26 years which has been shown to be 
highly cost-effective in many studies [8-13], relatively fewer cost-effectiveness analyses (CEA) 
on HPV vaccination have been conducted in other population groups. This study aims to 
investigate the cost-effectiveness of HPV vaccination program for women older than 26 years, 
heterosexual men and MSM and the factors that drive its cost-effectiveness through a literature 
review. 
Results 
Study Selection and Characteristics 
A total of 407 published articles were identified through PubMed (Figure 1). Initial screening 
eliminated 14 duplicated articles and a further 253 articles were excluded because they were not 
cost-effectiveness analyses of HPV vaccination. The remaining 140 articles were reviewed in 
full-text for eligibility according to our inclusion and exclusion criteria. Another 104 articles 
were excluded and 36 papers were eventually selected for our literature review. Among these 36 
studies, six reported on women over age 26, 26 on heterosexual men, four on MSM and one 
reported on both women over age 26 and heterosexual men. These studies were conducted in 17 
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countries (12 high-income countries (HICs) and five low- and middle- income countries 
(LMICs), Table 1). Most (64%, n=23) selected studies were published in 2011 or later. 
Cost-effectiveness of HPV vaccination for >26-year-old women 
Six studies [14-19] evaluated the cost-effectiveness of 2vHPV vaccine in women >26 years. Four 
studies [14, 15, 17, 19] found the costs for targeted vaccination for women >26 years  (ICER= 
US$65,000-192,000/QALY gained, Table S1) were beyond their respective cost-effectiveness 
thresholds (~$50,000/QALY gained) (Figure 2a). Four studies assumed vaccination cost 
US$283-400/3-dose vaccination schedule and concluded the program as not cost-effective. 
However, one study from the UK [14] showed marginal cost-effectiveness when vaccine price 
was below £20/dose and life-time vaccine protection for women when no loss of immunity over 
time was considered. Another study from Lao PDR [18] showed the program to be cost-effective 
with a catch-up vaccination for women up to age 75 years and the existing schoolgirls 
vaccination program was strongly subsidised by GAVI, the Vaccine Alliance (US$8.5/dose). 
Only one Belgium study [16] demonstrated their program to be very cost-effective with the 
2vHPV for women age up to 33 years (Table S1). Both the Lao PDR and Belgium studies 
assumed high vaccination coverage (≥70%). All studies assumed 3-dose vaccination strategies 
and none compare it with a 2-dose vaccination strategy. 
Cost-effectiveness of HPV Vaccination for Heterosexual men 
Of 26 selected studies [12, 20-43] on gender-neutral vaccination (three in LMICs and 23 in 
HICs), two studies examined 2vHPV vaccine, 20 on 4vHPV, and four on 9vHPV vaccines. 
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Sixteen studies [21-24, 26, 35-45] demonstrated that HPV vaccination for heterosexual men with 
an existing female program was cost-effective (ICER = $19,600-52,800/QALY gained in HICs 
and $49-5,860/QALY gained in LMICs, Table S1) with respect to their respective cost-
effectiveness thresholds (Figure 2a). 
All four studies that assessed 9vHPV [35, 37, 39, 41] vaccine concluded that the vaccine for both 
girls and boys was cost-effective (ICER=$8600-49800/QALY gained, Table S1) in comparison 
with 2vHPV or 4vHPV vaccination for both women and/or men. The majority (2/3) of studies 
with 2vHPV vaccination [23, 29] was not cost-effective, while 11/20 studies with 4vHPV 
vaccination were cost-effective. Interestingly, when stratified by five-year time periods (<2010, 
2010-2014 and ≥2015, Figure 2b), increasing proportion of studies demonstrated cost-
effectiveness of HPV vaccination for heterosexual men in recent years (p-value=0.035). 
The assumed price of HPV vaccines varied substantially across studies (US $10-130/dose), and 
our analysis did not show any correlation between vaccine price and program cost-effectiveness 
in heterosexual men. While 3-dose vaccination strategy showed mixed results (14 cost-effective 
and 11 not), both studies with a 2-dose vaccination strategy showed cost-effectiveness [44, 45]. 
Longer duration of vaccine protection (life time protection) and program evaluation (100 years 
horizon) led to lower ICERs in these studies. 
Age was an important factor for vaccine cost-effectiveness. Eight studies showed it was cost-
effective to expand existing schoolgirl program to cover schoolboys at the same age (<15 years). 
However, a UK study [27] and a Danish study [30] demonstrated that in the presence of a 
schoolgirl program, catch-up vaccination for young women up to 26 was a more cost-effective 
Ac
ce
pte
d M
an
us
cri
pt
 
8 
option than expanding schoolgirl program to cover the same age schoolboys. Eight studies 
showed that vaccination program for schoolboys and heterosexual men was no longer cost-
effective if the vaccination coverage in women was beyond 70-75%. There was no evidence that 
the countries’ economic development status and vaccine efficacy had any impact on the cost-
effectiveness of vaccination program for heterosexual men. 
Cost-effectiveness of HPV Vaccination for MSM 
Four studies [46-49] evaluated the cost-effectiveness of 4vHPV vaccine for MSM. All four 
studies demonstrated that the 4vHPV vaccine for MSM compared with no vaccination was cost-
effective ($15,000-43,000/QALY gained) (Figure 2 a, Table S1), and it showed lower ICERs, 
hence better cost-effectiveness, for vaccination against MSM at a young age (<40 years) or 
against those who were HIV-positive. A good cost-effectiveness of HPV vaccination for MSM 
was also associated with a high vaccination coverage (at least 55-80%), a potent vaccine efficacy 
(50-90%), a low vaccine price of 4vHPV (US$180-360/3-doses), a long duration of evaluation 
(life-time/100 years’ time horizon) (Table 2). In all MSM studies, there was no evidence that the 
socio-economic development status of the countries and vaccine dosage influenced the cost-
effectiveness of MSM vaccination. 
Vaccination and cervical cancer screening in included countries 
The HPV vaccination and cervical cancer screening programs from the selected studies were 
described in Table 1. The annual cervical cancer incidence was generally higher (9.4-23.7 versus 
5.5-12.9 per 100,000) in women from LMIC than HIC, as was the age standardized mortality 
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rate for cervical cancer (3.4-8.0 versus 1.4-2.1 per 100,000). Cervical cancer mortality rates were 
significantly and negatively correlated with Gross National Income (GNI) (Spearman, r=-0.75, 
p<0.001). Cervical cancer screening coverage among targeted women in HIC was more than 50-
70%. In contrast, among LMIC, only Brazil reached a similar screening coverage as in HIC, 
while other countries were consistently below 40%. All National HPV vaccination programs for 
schoolgirls (up to age 14) were introduced before 2011 in HIC, and some programs included a 
catch-up program for young women up to age 26. To date, Austria, Australia, Canada, and the 
US, have expanded the vaccination program to schoolboys (age 9-14 years). In contrast, HPV 
vaccination began much later in LMICs, typically between 2013 and 2015 and China and 
Vietnam did not implement any vaccination programs until 2017. Vaccination coverage for 
women ranged from 40-80% in developed countries, where Germany had the lowest (40%) and 
the United Kingdom the highest (80%) coverage. We found no significant correlation between 
GNI per capita and vaccination coverage (R=-0.0049, p=0.9877). 
Discussion 
Our targeted literature review indicated that HPV vaccine for women >26 years would not be 
cost-effective, and this is consistent with current policy and practice. In contrast, HPV 
vaccination for heterosexual men demonstrated mixed results: programs proposing 9vHPV 
(compared with 4vHPV and 2vHPV), those assuming a long duration of vaccine effectiveness 
and those vaccinating young heterosexual men (<26) demonstrated cost-effectiveness. Further, it 
suggested that targeted HPV vaccination for MSM is cost-effective in all four included studies. 
A previous systematic review on the cost-effectiveness of HPV vaccination among adolescent 
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girls in LMICs has shown that vaccine price is one of the key determinant of vaccination cost-
effectiveness [50]. Our review further confirms this is also true in heterosexual men and MSM. 
In addition, we also identified a broad genotype coverage (9vHPV), less required doses and 
longer vaccine protection are important determinants for cost-effectiveness. 
Our findings suggests that targeted HPV vaccination for MSM should be a priority worldwide. 
Unlike heterosexual men, MSM may benefit to a lesser extent from the herd immunity that 
heterosexual men may receive from the female vaccination programs [51]. On the other hand, 
MSM are much more at-risk than heterosexual men to HPV infection in particular anogenital 
warts and anal cancer. In contrast to vaccination program in women where the vaccination 
coverage required (~70%) is well established, the vaccination coverage required in MSM to 
achieve the same level of herd immunity that heterosexual men may experience is not known. 
Since the reproductive rate of HPV infection in MSM is much greater than heterosexual men, it 
is likely that a higher level of vaccination coverage will be required [52]. 
Despite only 16 of 26 studies in heterosexual men demonstrating cost effectiveness, our data 
suggest that a gender neutral vaccination strategy may become increasingly cost-effective for a 
number of reasons. First, recent literatures reported that 1- or 2-doses vaccination is as effective 
as 3-doses vaccination for people age 9-14 years, which means a potential 30% cost reduction 
per head if this is implemented in any school age vaccination programs [53-55]. Second, it is 
anticipated that the mean price of HPV vaccine for LMICs will continue to decline over time, 
especially with significant subsidies and influence from major international health organizations 
such as GAVI, UNICEF and Pan American Health Organization (PAHO) [56, 57]. 
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Our analysis shows no correlation between individual country’s socio-economic status and 
vaccination coverage. However, we argue that the rollout of a universal HPV vaccination 
program in LMICs may face more challenges. Given limited resources, LMICs generally have a 
lower willingness-to-pay threshold for a vaccination program. Therefore, vaccine cost needs to 
be substantially lowered in LMICs, not only for the consideration of cost-effectiveness, but also 
the upfront investment cost must not become an excessive financial burden to the country 
budget. The initial rollout of the program often require a one-time investment for health 
facilities, establishment of an efficient implementation system and training for healthcare staff. 
Further, in resource-poor settings, an efficient healthcare provision system is often absent to 
provide the scheduled vaccination program, which is an essential infrastructure for additional 
HPV vaccination programs. For these settings, resources from the international community 
should be directed to provide point-of-care vaccination where primary healthcare is absent, and 
2-dose HPV vaccine should be promoted to improve vaccination coverage in the population. 
A number of limitations need to be considered when interpreting our results. As a targeted 
literature review, we excluded studies not published in English and therefore, our study may be 
subject to publication bias. Second, we could not conduct a meta-analysis due to limited data 
available from targeted reviews. Similarly, we could not prove the robustness of outcomes 
because of the variations in models applied in the included studies where different assumptions 
and parameters were used. For instance, population impact was not reported in a consistent form 
across the studies, however, we emphasized that all cost-effectiveness studies included a baseline 
scenario and the analysis was conducted by comparing the scenarios in the presence and absence 
scenario. Therefore, we summarized the absolute number of studies and the factors influencing 
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the cost-effectiveness instead. Despite these limitations, we believe our findings would be a 
springboard for further studies of the cost-effectiveness of HPV vaccination for these currently 
untargeted populations. 
Conclusion 
Targeted HPV vaccination for MSM should be next priority in HPV prevention after having 
established a solid girls vaccination programme. Vaccination for heterosexual men should be 
considered when 2-dose 4vHPV/9vHPV vaccines become available with a reduced price. 
Vaccination for women over age 26 may not be cost-effective until the vaccine price is further 
reduced. 
Method 
Search 
The full electronic search was conducted in PubMed for related articles and reviews on February 
15th 2017, which were published in the English language from January 1, 2000 to December 31, 
2016. The search strategy was conducted using the following key words: “Human 
Papillomavirus” AND “Cost-effectiveness” AND “Vacc*” in MeSH terms AND “HPV” OR 
“Human Papillomavirus” AND “Cost-effective*” AND “Vacc*” in titles and abstracts AND 
“English” in language. 
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Eligibility Criteria 
This review included English-language articles (published between 2000-2016) that assessed the 
incremental cost-effectiveness ratio (ICER) of HPV vaccination to the female population older 
than 26 years, heterosexual men and MSM, in comparison with the cost-effectiveness of existing 
cervical cancer screening or vaccination in young adolescent girls with a catch-up program for 
women age up to 26 years. In this review, the PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses) statement [58] was followed (Figure 1). Articles were 
excluded if they (1) were in a language other than English; (2) did not report ICER of the HPV 
vaccination program; and (3) only focused on young female vaccination program. 
Data collection 
We collected demographic data, HPV epidemiological data, impact and cost-effectiveness data 
from aforementioned literature review. In addition, based on the countries identified from the 
selected studies, we further collected data on country-specific HPV-related programs and country 
incomes that were not available in the literature research. 
First, demographic data included age and sex of the targeted population, period of analysis 
(retrospective or prospective study) and country of the study population. Second, 
epidemiological data included status quo HPV disease burden, subtypes and vaccination 
coverage. Third, population impact data included the type of model used, reduction in HPV 
infections, number of genital warts, pre-cancerous lesions CIN-1, -2, and -3 cases, cervical 
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cancer cases and mortality. Fourth, cost-effectiveness data included incremental cost associated 
with HPV vaccination programs; incremental cost-effectiveness ratios (ICERs); incremental life-
years gained (LYGs) or Quality-adjusted life-years (QALYs) gained from a vaccination 
program. Fifth, we identified 17 countries from the selected 36 publications. For these 17 
countries, we collected other HPV-related program and income data from these well-known 
online HPV databases: HPV Information Centre [59]; National Cancer Institute [60]; and 
International Agency for Research on Cancer [61]. Specific country data included: gross 
National Income per capita (GNI); age-standardized incidence rate of cervical cancer; age-
standardized mortality rate of cervical cancer; existence of national cervical cancer screening and 
HPV vaccination programs; years of introduction of the national HPV vaccination program; 
targeted age and gender of current HPV vaccination program; vaccination coverage; and cervical 
cancer screening coverage. Double-entry was performed to extract these data by two independent 
investigators (NNS, FC). Microsoft excel 2013 was used to store and analyse these data. 
Quality Assessment 
The quality assessment of each included study was conducted by two independent investigators 
(NNS, FC). Any conflicting opinions were resolved by a third reviewer (LZ). The quality check 
for each included study was assessed by three domains: study design, data collection, and 
analysis and interpretation of the results (Cost-effectiveness study quality checklist [62], Table 
S2). 
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Data Analysis 
Descriptive statistics were conducted for each study population group (older women, 
heterosexual men and MSM) to inform HPV program, impact and cost-effectiveness indicators. 
First, for each population, we categorized the selected studies that showed proposed strategy was 
cost-effective according to their stated willingness-to-pay threshold, and those showed it was not 
cost-effective. Second, the major contributing factors influencing the cost-effectiveness, 
including vaccination age and coverage, vaccine efficacy, price and dosage, duration of vaccine 
protection, and the time horizon of evaluation, were identified in both cost-effective and non-
cost-effective studies. A Spearman’s correlation test was used to analyse the correlation between 
the GNI and HPV-burden of the included countries. In addition, chi-square tests were conducted 
to investigate the time trend of cost-effectiveness of HPV vaccination for heterosexual males. 
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in this targeted review.
Ac
ce
pte
d M
an
us
cri
pt
 
34 
 
Study 
Stu
dy 
yea
r 
Count
ry 
Baselin
e 
strateg
y 
Propose
d 
strategy 
(targete
d 
populat
ion size 
if 
applica
ble) 
Key 
study 
paramet
ers 
Durati
on of
evaluat
ion 
Cost-
effectiveness 
(ICER=cost/Q
ALY gained) 
Epidemiolo
gical 
impacts 
over 
evaluation 
period 
Authors' 
conclusio
ns 
Heterosexual men 
Al V. 
Taira, 
et al. 
[20] 
200
4 
USA 12yr GF
with 
2vHPV, 
n=U.S 
GF 
populati
on  
FM with 
2vHPV 
vaccinat
ion  
US$300/
3-
dose/per
son; 
3.5% 
DR; 90% 
VE; at 
least 
2001-
lifetime
US$442,039 
12GF-only 
vaccination 
reduced CC
by 61.8%, 
FM 
vaccination 
further 
reduced CC
Not cost-
effective 
(WTP:  
US$100,0
00) 
Ac
ce
pte
d M
an
us
cri
pt
 
35 
10yr 
protectio
n; 70% 
coverage
, 
by 2.2%  
Jane J. 
Kim, 
et al. 
[23] 
200
7 
  
 
Brazil 
  
 
No 
vaccinat
ion for
FM  
  
 
FM, 
with 
2vHPV 
  
I$50/3-
dose/per
son; 3% 
DR; 
100% 
VE; 
lifetime 
protectio
n; 0-90% 
coverage
Not 
reporte
d 
  
  
  
25% coverage:
I$810/LYG 
GF-only 
vaccination 
reduced CC
risk by 63%, 
FM 
vaccination 
further 
reduced CC
risk by 4% 
  
  
  
Cost-
effective 
(WTP: 
I$8,600/L
YG) 
50% coverage:
I$1,740/LYG 
Cost-
effective 
75% coverage:
I$2,180/LYG 
Cost-
effective 
90% coverage:
I$1,8650/LYG
Not cost-
effective 
Anna R. 200 USA 12yr 12yr Not -- US$45,056 GW, CINCost-
Ac
ce
pte
d M
an
us
cri
pt
 
36 
Giuliano 
[21] 
7 FM +
12-24yr 
CU with
4vHPV  
FM + 
12-24yr 
CU-FM) 
with 
4vHPV, 
n=536 
(F: 299, 
M: 237) 
reported and CC
reduced by
97%, 91%
and 91%
respectively 
effective 
Shalini 
Kulasing
am, et al. 
[24] 
200
7 
Austra
lia 
No 
vaccinat
ion for
FM 
12yr 
FM with 
2vHPV 
+ 14-
26yr 
with 
2vHPV, 
US$345/
3-
dose/per
son; 3% 
DR; 
100% 
[93-
100%] 
VE; 
lifetime 
protectio
n; 80% 
2005- 
2078 
US$33,644 
[24,988-
68,158] 
-- Cost-
effective 
Ac
ce
pte
d M
an
us
cri
pt
 
37 
coverage
Elamin 
H. 
Elbasha, 
et al. 
[22] 
200
7 
 
USA 
 
12yr GF
with 
current 
vaccinat
ion 
12yr 
FM with 
4vHPV 
n=100,0
00 
(F:50%, 
M:50%) 
US$360/
3-
dose/per
son; 3% 
DR; 90-
100% 
VE; 
lifetime 
protectio
n; 70% 
coverage
2005- 
2105 
Dominated  Not cost-
effective 
(WTP: 
US$100,0
00) 
12yr GF
+ 12-
24yr 
CU  
12yr 
FM + 
12-24yr 
CU 
  $4,666  Cost-
effective 
12yr 
FM +
12-24yr 
12yr 
FM + 
12-24yr 
  $45,056  GW, CIN,
and CC
reduced by
Cost-
effective 
Ac
ce
pte
d M
an
us
cri
pt
 
38 
CU CU-FM 97%, 91%,
and 91%,
respectively 
Ralph P. 
Insinga, 
et al. 
[12] 
200
7 
  
  
Mexic
o 
  
  
12yr GF
with 
4vHPV 
12yr 
FM with 
4vHPV, 
n=1000
00 
US$240/
3-
dose/per
son; 3% 
DR; 90% 
VE; 
lifetime 
protectio
n; 70 
[20-
85]% 
coverage
2007-
2066 
US$2,719 FM 
vaccination 
reduced CC,
CIN and
GW by 84-
98% 
Not cost-
effective 
(WTP: 
US$30,00
0) 
12yr GF
+ 12-
24yr 
CU 
12yr 
FM + 
12-24yr 
CU 
  US$16,663  Cost-
effective 
Ac
ce
pte
d M
an
us
cri
pt
 
39 
 
 
12yr 
FM +
12-24yr 
CU-FM 
12yr 
FM + 
12-24yr 
CU-FM 
  US$16,702  Cost-
effective 
Ac
ce
pte
d M
an
us
cri
pt
 
40 
 
Study 
Stu
dy 
yea
r 
Count
ry 
Baselin
e 
strategy
Propose
d 
strategy 
(targete
d 
populat
ion size
if 
applica
ble) 
Key 
study 
paramet
ers 
Durati
on of 
evaluat
ion 
Cost-
effectiveness 
(ICER=cost/Q
ALY gained) 
Epidemiolo
gical 
impacts 
over 
evaluation 
period 
Authors' 
conclusio
ns 
Ac
ce
pte
d M
an
us
cri
pt
 
41 
Mark Jit, 
et al. [31] 
200
8 
  
  
UK 
  
  
12yr GF 
+ 12-
25yr 
CU with 
4vHPV 
  
12yr FM
with 
4vHPV 
vaccinat
ion 
£210 
[180-
240]/3-
dose/pers
on; 3.5% 
DR; 
100% 
VE; 
lifetime 
protectio
n; 80% 
coverage
2007- 
2107 
  
  
Lifetime 
protection:  
£520,255 
[304,798-
986,917] 
-- 
 
Not cost-
effective
(WTP: 
£30,000)
20yr 
protection:  
£172,892  
[112,230-
289,698] 
Not cost-
effective 
10yr 
protection:  
£113,846 
[71,099-
176,749] 
Not cost-
effective 
Ac
ce
pte
d M
an
us
cri
pt
 
42 
Ingrid 
Zechmeis
ter,  
et al. [28] 
200
9 
Austri
a 
12yr 
GF, 
with 
2vHPV  
12yr 
FM, 
with 
4vHPV 
€330/3-
dose/pers
on; 5% 
DR; 90% 
VE; 10-
year to
lifelong 
protectio
n; 65% 
coverage
2008- 
2060 
€299,000-
311,000/LYG 
-- Not cost-
effective 
Jane J. 
Kim and 
Sue 
Goldie 
[29] 
 
200
9 
  
USA 
  
12yr 
GF, 
with 
2vHPV  
12yr 
FM, 
with 
2vHPV 
and 
current 
screenin
g for
triage  
US$360/
3-
dose/pers
on; 3% 
DR; 
100% 
VE in 
GF & 
90% in 
2006- 
2106 
  
US$114,510 Cases 
attributable 
to vaccine 
targeted 
types 
reduced by 
50% 
Not cost-
effective
(WTP: 
US$100,
000) 
Ac
ce
pte
d M
an
us
cri
pt
 
43 
12yr FM
with 
2vHPV 
and 
current 
screenin
g for
triage 
until 
30yr, &
cytology 
and 
HPV 
DNA 
testing 
after age
30 
GM; 
lifetime 
protectio
n; 75% 
coverage
  
US$120,300 Not cost-
effective 
Ac
ce
pte
d M
an
us
cri
pt
 
44 
Elamin 
H. 
Elbasha, 
et al. [26] 
201
0 
USA 9-26yr 
GF with 
vaccinat
ion 
9-26yr 
FM with
4vHPV 
US$400/
3-
dose/pers
on; 3% 
DR; 90% 
VE; 
lifetime 
protectio
n; 50-
90% 
vaccine 
coverage
2008- 
2108 
CD 
considered: 
$195,322 
[87,426-
570,330], 
All outcomes
considered: 
$25,664 
[13,605-
48,816] 
Prevented 
30,750 CC, 
707,489 
CIN-2/3, 
1,849,170 
GW (F); 
3297418 
GW (M). 
Cost-
effective
(WTP: 
US$20,0
00 –
50,000)  
Jens 
Olsen, et 
al. [30] 
201
0 
Denm
ark 
12yr GF 
+ 12-
26yr 
CU with 
4vHPV 
12yr FM
with 
4vHPV,
n=2500
0 
£415/3-
dose/pers
on; 3% 
DR; 
100% 
VE; 70% 
coverage
2007- 
2068 
 £18,677 -- Not cost-
effective 
Ac
ce
pte
d M
an
us
cri
pt
 
45 
Harrell 
W. 
Chesson, 
et al. [27] 
  
  
  
201
1 
  
  
  
  
USA 
  
  
12-26yr 
GF with 
4vHPV  
12yr FM
+ 12-
26yr 
CU-GF 
with 
4vHPV,
n=191 
US$500 
[360-
600]/3-
dose/pers
on; 3% 
DR; 90-
95% VE; 
lifetime 
protectio
n; varied 
coverage
2008- 
2108 
20% coverage:
$23,600 
[11,400-
39,500] 
CC to 
HPV16/18 
reduced by 
81.3%, 
67.4%, and 
97.4%, with 
30%, 20%, 
and 75% 
coverage, 
respectively. 
Cost-
effective
(WTP: 
US$100,
000) 
30% coverage:
$41,400 
[23,400-
64,300] 
Cost-
effective 
75% coverage:
$184,300 
[115,000-
276,300] 
Not cost-
effective 
Ac
ce
pte
d M
an
us
cri
pt
 
46 
 
  
12yr GF 
with 
4vHPV 
30% 
coverag
e 
12yr FM
with 
4vHPV 
30% 
coverag
e 
$25,000 Cost-
effective 
   12yr GF 
with 
4vHPV 
45% 
coverag
e 
12yr FM
with 
4vHPV 
30% 
coverag
e 
$103,500 Not cost-
effective 
Ac
ce
pte
d M
an
us
cri
pt
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MSM=Men-who-have-sex-with-men; GM=Heterosexual men; GF=Women; FM=Males and women; CU=Catch-up; DR=Discounted rate; 
VE=Vaccine efficacy; yr=years; NoVac=No vaccination; HR=Hazard ratio; 2vHPV=Bi-valent vaccine; 4vHPV=Quadri-valent vaccine; 9vHPV=Nona-
valent vaccine; ANA=Anal cancer; GW=Genital warts; CC=Cervical Cancer; CIN=Cervical intraepithelial neoplasia; QALY=Quality-adjusted life 
year; LYG=Life years gained; WTP=Willingness-to-pay thresholds; Dominated=the intervention is less effective and more costly; CD=Cervical 
diseases 
 
Study 
Stu
dy 
yea
r 
Cou
ntry 
Baseline 
strategy 
Propose
d 
strategy 
(targete
d 
populat
ion size 
if 
applica
ble) 
Key 
study 
paramete
rs 
Durati
on of 
evaluat
ion 
Cost-
effectiveness 
(ICER=cost/
QALY 
gained) 
Epidemiolo
gical 
impacts 
over 
evaluation 
period 
Authors
' 
conclusi
ons 
Ac
ce
pte
d M
an
us
cri
pt
 
48 
Amber L 
Pearson, et 
al. [25] 
  
201
4 
  
New 
Zeal
and 
  
12yr GF,
with 
4vHPV  
n=total 
populatio
n 
12yr 
FM, 
with 
4vHPV 
US$400/3
-
dose/pers
on; 3% 
DR; 99% 
VE; 20yr 
protection
; 
Interventi
on 1G: 56 
[54-58] % 
coverage; 
Interventi
on 2G: 73 
[68-78] % 
coverage,
-- 
  
$118,000 
[57,100-
215,000] 
--  Not 
cost-
effective
(WTP: 
US$29,6
00) 
12yr GF,
with 
4vHPV 
(Intensiv
e 2G GF-
only 
program) 
12yr 
FM, 
with 
4vHPV 
$247,000 
[119,000-
474,000] 
Not 
cost-
effective
Ac
ce
pte
d M
an
us
cri
pt
 
49 
Jean-Franc 
ois 
Laprise, et 
al. [32] 
201
4 
  
Cana
da 
  
GF with
2-doses 
4vHPV 
FM 
with 2-
doses 
4vHPV,
n= 
170000 
Cost: 
CA$85/d
ose; 3% 
DR; 90-
95% VE; 
2-dose: 
10-30yr 
protection
; 3-dose: 
20yr-
lifelong 
protection
; 80% 
coverage,
2014- 
2083 
  
2-dose: 
CA$87,042 
[70,141-
133,239] 
Prevented 
an extra 3% 
HPV-
related 
cancer and 
9% GW 
cases to F-
only Vac 
(12-13% 
reduction of 
cancers & 
GW)  
Not 
cost-
effective
(WTP: 
CA$40,
000) 
GF with
3-doses 
4vHPV 
(or) FM
with 2-
doses 
4vHPV  
FM 
with 3-
doses 
4vHPV
3-dose: 
>CA$100,000
Not 
cost-
effective
Wanrudee 
Isaranuwat
chai, et al. 
[33]  
201
4 
  
USA 
  
12yr GF
with 
4vHPV 
12yr 
FM, 
with 
4vHPV 
US$500/3
-
dose/pers
on 
 
-- 
  
US$115,000 -- 
  
Not 
cost-
effective
(WTP: 
$40,000)
Ac
ce
pte
d M
an
us
cri
pt
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12yr GF
with 
4vHPV 
9-26yr 
FM 
with 
4vHPV 
  
US$70,000 Not 
cost-
effective
Ac
ce
pte
d M
an
us
cri
pt
 
51 
Emily A. 
Burger., et 
al. [44]  
201
4 
Nor
way 
12yr GF
with 
4vHPV 
12yr 
FM 
with 
4vHPV 
Market 
price: 
US$150/d
ose; 
Nationall
y 
negotiate
d tender 
price: 
US$75/do
se; 4% 
DR; 90 -
100% 
VE; 
lifetime 
protection
; 71-79% 
coverage 
2013-
lifetime
US$81,700 
considering 
only cancer 
for FM,
US$60,100 
considering all 
HPV-related 
conditions, 
CC 
reduction 
varies, 
reduced GF 
GW 85%, 
GM GW 
84%. 
Margina
lly cost-
effective
(WTP: 
US$83,0
00) 
Ac
ce
pte
d M
an
us
cri
pt
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MSM=Men-who-have-sex-with-men; GM=Heterosexual men; GF=Women; FM=Males and women; CU=Catch-up; DR=Discounted rate; 
VE=Vaccine efficacy; yr=years; NoVac=No vaccination; HR=Hazard ratio; 2vHPV=Bi-valent vaccine; 4vHPV=Quadri-valent vaccine; 9vHPV=Nona-
valent vaccine; ANA=Anal cancer; GW=Genital warts; CC=Cervical Cancer; CIN=Cervical intraepithelial neoplasia; QALY=Quality-adjusted life 
year; LYG=Life years gained; WTP=Willingness-to-pay thresholds; Dominated=the intervention is less effective and more costly; 
  
Xavier 
Bresse, et 
al. [43] 
201
4 
Aust
ria 
9yr FM
without 
vaccinati
on 
9yr FM 
with 
4vHPV
€360/3-
dose/pers
on; 3% 
DR; 
GF:76-
100%, 
GM:41-
96% VE; 
lifetime 
protection
; 65% 
coverage 
2014- 
2114 
 €10,033-
26,701 
Prevented 
9,500 GW 
annually 
and 431 
HPV 16/18-
related 
can ers in 
FM 
Cost-
effective
Ac
ce
pte
d M
an
us
cri
pt
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Study 
Stu
dy 
yea
r 
Country 
Baseline 
strategy 
Proposed 
strategy 
(targeted 
populati
on size if 
applicabl
e) 
Key 
study 
parame
ters 
Durati
on of 
evalua
tion 
Cost-
effectiveness 
(ICER=cost/
QALY 
gained) 
Epidemiol
ogical 
impacts 
over 
evaluation 
period 
Author
s' 
conclus
ions 
Donna 
M. 
Graham, 
et al. 
[36] 
  
201
5 
  
Canada 
  
No 
vaccinatio
n for
heterosex
ual men 
  
Up to 
12yr 
male, 
with 
4vHPV, 
 
  
CA$400
/3-
dose/per
son; 5% 
DR; 84 
[50-
99]% 
VE. 50-
70% 
coverag
e 
2014-
lifetim
e 
  
99% VE & 
70% uptake: 
saved 
$145/individ
ual (0.05 
more QALY) 
-- 
  
Cost-
effectiv
e 
 
50% VE & 
50% uptake: 
saved 
$42/individu
al (0.023 
more 
Cost-
effectiv
e 
Ac
ce
pte
d M
an
us
cri
pt
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QALYs) 
Jens 
Olsen, 
et al. 
[45] 
201
5 
  
Denmark 
  
12yr GF,
with 
4vHPV 
  
12yr FM, 
with 
4vHPV 
  
US€369/
3-
dose/per
son; 3% 
DR; 
100% 
VE; 
lifetime 
protectio
n; 85% 
coverag
e, 
2014- 
2075 
  
3-dose:  
€41,636 and 
€40,615/LY
G 
2-dose: 
€28,031 
5 CC, 34
ANA, 98
H&N 
cases 
avoided 
per year 
  
Cost-
effectiv
e 
(WTP:  
€ 
50,000)
Nikolao
s 
Kotsopo
ulos, et 
al. [42] 
201
5 
Germany No 
vaccinatio
n for FM 
12yr FM, 
with 
4vHPV, 
n = 
400,000 
€244/2-
dose/per
son; 
2.4% 
DR; 78-
100% 
VE; 
2015-
lifetim
e 
Investing €1 
in universal 
HPV 
vaccination 
could yield 
€1.7 in gross 
tax revenue 
Prevented 
857 cancer
deaths, 
1,527 CC,
286 ANA,
228 VAG,
116 VUL,
Cost-
effectiv
e 
Ac
ce
pte
d M
an
us
cri
pt
 
55 
55% 
coverag
e 
over the 
lifetime of 
the cohorts.  
45,809 
GW, and
127,464 
CIN I-III 
Katrin 
Haeussl
er, et al. 
[38] 
  
201
5 
  
Italy 
  
GF 
without 
vaccinatio
n 
(screenin
g) 
12yr FM 
with 
4vHPV, 
n=149,73
6,770 
€40-
140/dos
e; 3% 
DR; 
50% 
VE; 
lifetime 
protectio
n; 90 
[66-100] 
% 
coverag
e, 
2015-
2070 
  
 €1,500 -- 
  
Highly 
cost-
effectiv
e  
(WTP: 
€25,00
0-
€40,00
0) 
GF with
4vHPV 
12yr FM 
with 
4vHPV  
 
€11,600[10,1
73-13,227] 
Cost-
effectiv
e 
M 
Sharma, 
et al. 
201
6 
Southern 
Vietnam 
≥9yr GF,
with 
≥ 9yr 
FM, with 
I$10-
200/3-
dose/per
2015-
longti
≤$25/dose: 
I$49-1,751 
F-only 
Vac: CC
risk 
Cost-
effectiv
e 
Ac
ce
pte
d M
an
us
cri
pt
 
56 
[40]  4vHPV   4vHPV  son; 3% 
DR; 
100% 
VE for 
GF; 
85% for 
GM; 
lifetime 
protectio
n; 25-
90% 
coverag
e 
me reduced by
20%-
56.9%. 
FM Vac:
<=3.6% 
higher 
absolute 
CC risk
reduction.  
(WTP: 
I$2,800
) 
≥$25-
75/dose: 
I$1,445-
5,860 
Margin
ally 
cost-
effectiv
e 
>$75/dose: 
I$3,190-
16,131 
Not 
cost-
effectiv
e 
Nathalie 
Largero
n, et al. 
[41]  
201
6 
Germany 9-17yr 
GF with
4vHPV 
vaccinatio
n 
9-17yr 
FM, with 
9vHPV 
vaccinati
on 
€336/3-
dose/per
son for 
4vHPV; 
€372/3-
dose/per
son for 
2015-
2115 
 €22,987 
/QALY 
•
 Pre
vented 
46,454 
CC, 
398,993 
CIN1, 
Cost-
effectiv
e 
(WTP: 
€40,00
0) 
Ac
ce
pte
d M
an
us
cri
pt
 
57 
9vHPV; 
3% DR; 
varied 
VE; 
lifetime 
protectio
n; varied 
coverag
e, 
571013 
CIN2+, 
315 VAG,
429 VUL,
364,313 F
GW, 3,036
GF ANA,
1,084,422 
GM GW &
5,420 GM
ANA. 
David P. 
Durham
a, et al. 
[35]  
201
6 
USA FM with
2vHPV/4
vHPV  
FM, with 
9vHPV, 
n=10000
US$148/
dose for 
9vHPV; 
US$135/
dose for 
4vHPV; 
US$129/
dose for 
2vHPV; 
 2015-
2050 
When 
considering 
Costs: 
US$32,809-
49,363, 
When 
considering 
total societal 
cost: 
US$21,398-
•
 Re
duced CC
incidence 
by 73%
and 
mortality 
by 49%
compared 
to NoVac
Cost-
effectiv
e 
(WTP: 
US$53,
000) 
Ac
ce
pte
d M
an
us
cri
pt
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3% DR 49,796 (15,947 
CC, 4,912
mortality). 
MSM=Men-who-have-sex-with-men; GM=Heterosexual men; GF=Women; FM=Males and women; CU=Catch-up; DR=Discounted rate; VE=Vaccine efficacy; yr=years; NoVac=N
vaccine; 9vHPV=Nona-valent vaccine; ANA=Anal cancer; GW=Genital warts; CC=Cervical Cancer; CIN=Cervical intraepithelial neoplasia; QALY=Quality-adjusted life year; LYG=L
intervention is less effective and more costly;
Ac
ce
pte
d M
an
us
cri
pt
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Study 
Stu
dy 
year 
Count
ry 
Baseli
ne 
strate
gy 
Propose
d 
strategy 
(targete
d 
populati
on size if
applicab
le) 
Key 
study 
paramet
ers 
Duratio
n of 
evaluati
on 
Cost-
effectiveness 
(ICER=cost/Q
ALY gained) 
Epidemiolog
ical impacts 
over 
evaluation 
period 
Authors' 
conclusi
ons 
Ac
ce
pte
d M
an
us
cri
pt
 
60 
Harrell 
W. 
Chesso
n, et 
al. [37] 
2016USA FM 
with 
4vHP
V  
FM with
9vHPV, 
n=191 
$435/3-
dose/pers
on for 
4vHPV; 
$474[453
-513]/3-
dose/pers
on for 
9vHPV; 
3% DR; 
95[85-
100]% 
VE; 
lifetime 
protectio
n; 
GF:70%, 
GM:50% 
coverage
2015- 
2115 
No cross-
protection for 
4vHPV: <$0, 
Cross-
protection for 
4vHPV: 
US$8,600 
With 4vHPV, 
CIN reduced 
by 43-53%, 
With 9vHPV, 
CIN reduced 
by 63-65% 
Cost-
saving 
Ac
ce
pte
d M
an
us
cri
pt
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L. 
Boiron
, et al. 
[39]  
2016Austri
a 
9yr 
FM 
with 
4vHP
V  
9yr FM
with 
9vHPV 
€297/2-
dose/pers
on for 
9vHPV; 
3% DR; 
Varied 
VE; 
lifetime 
protectio
n, GF: 
60%, 
GM: 
40% 
coverage
2016- 
2116 
 €16,441   Prevented an 
additional 
14,893 
CIN2/3 and 
2,544 CC 
Cost-
effective
(WTP: 
€30,000)
Ac
ce
pte
d M
an
us
cri
pt
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Table 2. Cost-effectiveness study quality checklist 
Item 
MSM Older genereal females 
Ja
ne
 J.
 K
im
[4
9]
  
et
 a
l.[
47
] 
et
 a
l.[
46
] 
A
lle
n 
Li
n[
48
] 
Ja
ne
 J.
 K
im
, e
t a
l.[
15
] 
a l
.[1
7]
 
a l
.[1
6]
 
a l
.[1
4]
 
Y
i-J
un
 L
iu
, e
t a
l.[
19
] 
a l
.[1
8]
 
Study 
design 
                    
The 
research 
question 
is stated 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
The 
economi
c 
importan
ce of the 
research 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
63 
question 
is stated 
The 
viewpoi
nt(s) of 
the 
analysis 
are 
clearly 
stated 
and 
justified 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
The 
rationale 
for 
choosing 
alternati
ve 
program
mes or 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
64 
intervent
ions 
compare
d is 
stated 
The 
alternati
ves 
being 
compare
d are 
clearly 
describe
d 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
The 
form of 
economi
c 
evaluati
on used 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
65 
is stated 
The 
choice 
of form 
of 
economi
c 
evaluati
on is 
justified 
in 
relation 
to the 
question
s 
addresse
d 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Data 
collectio
n 
                    
Ac
ce
pte
d M
an
us
cri
pt
 
66 
The 
source(s
) of 
effective
ness 
estimate
s used 
are 
stated 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Details 
of the 
design 
and 
results 
of 
effective
ness 
study 
are 
given (if 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ NA ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
67 
based on 
a single 
study) 
Details 
of the 
methods 
of 
synthesi
s or 
meta-
analysis 
of 
estimate
s are 
given (if 
based on 
a 
synthesi
s of a 
number 
of 
NA NA NA NA NA NA NA NA ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
68 
effective
ness 
studies) 
The 
primary 
outcome 
measure
(s) for 
the 
economi
c 
evaluati
on are 
clearly 
stated 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Methods 
to value 
benefits 
are 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
69 
stated 
Details 
of the 
subjects 
from 
whom 
valuatio
ns were 
obtained 
were 
given 
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ 
Producti
vity 
changes 
(if 
included
) are 
reported 
separatel
NA NA NA NA NA NA NA NA NA NA 
Ac
ce
pte
d M
an
us
cri
pt
 
70 
y 
The 
relevanc
e of 
producti
vity 
changes 
to the 
study 
question 
is 
discusse
d 
NA NA NA NA NA NA NA NA NA NA 
Quantiti
es of 
resource 
use are 
reported 
separatel
y from 
NA NA NA NA NA NA NA NA NA ✗ 
Ac
ce
pte
d M
an
us
cri
pt
 
71 
their 
unit 
costs 
Methods 
for the 
estimati
on of 
quantitie
s and 
unit 
costs are 
describe
d 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Currenc
y and 
price 
data are 
recorded 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Details ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
72 
of 
currency 
of price 
adjustme
nts for 
inflation 
or 
currency 
conversi
on are 
given 
Details 
of any 
model 
used are 
given 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
The 
choice 
of model 
used and 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
73 
the key 
paramet
ers on 
which it 
is based 
are 
justified 
Analysis 
and 
interpre
tation of 
results 
                    
Time 
horizon 
of costs 
and 
benefits 
is stated 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
The ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
74 
discount 
rate(s) is 
stated 
The 
choice 
of 
discount 
rate(s) is 
justified 
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ 
An 
explanat
ion is 
given if 
costs 
and 
benefits 
are not 
discount
ed 
NA NA NA NA NA NA NA NA NA NA 
Ac
ce
pte
d M
an
us
cri
pt
 
75 
Details 
of 
statistica
l tests 
and CIs 
are 
given 
for 
stochasti
c data 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
The 
approac
h to 
sensitivit
y 
analysis 
is given 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
The 
choice 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
76 
of 
variables 
for 
sensitivit
y 
analysis 
is 
justified 
The 
ranges 
over 
which 
the 
variables 
are 
varied 
are 
justified 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Relevant 
alternati
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
77 
ves are 
compare
d 
Increme
ntal 
analysis 
is 
reported 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Major 
outcome
s are 
presente
d in a 
disaggre
gated as 
well as 
aggregat
ed form 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
The ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
78 
answer 
to the 
study 
question 
is given 
Conclusi
ons 
follow 
from the 
data 
reported 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Conclusi
ons are 
accompa
nied by 
the 
appropri
ate 
caveats 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
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✗, no; 
✓, yes; 
NA, not 
applicab
le. 
Ac
ce
pte
d M
an
us
cri
pt
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Study 
Stu
dy 
yea
r 
Coun
try 
Baselin
e 
strateg
y 
Propose
d 
strategy 
(targete
d 
populat
ion size
if 
applica
ble) 
Key study
parameters
Durati
on of 
evaluat
ion 
Cost-
effectiveness 
(ICER=cost/
QALY 
gained) 
Epidemiolo
gical 
impacts 
over 
evaluation 
period 
Authors
' 
conclusi
ons 
Ac
ce
pte
d M
an
us
cri
pt
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MSM 
Jane J.
Kim 
[49]  
  
201
0 
  
  
USA 
  
  
No 
vaccinat
ion for 
MSM 
  
  
Vaccina
te MSM
up to
12, 20
and 
26yr 
with 
4vHPV 
  
  
US$500/3-
dose/person; 
3% DR;
90% VE;
lifetime 
protection; 
50% 
coverage. 
2006-
lifetime
  
  
12yr: $15,207
[$10,100-
28,824] 
-- 
  
  
Cost-
effective
(WTP: 
US$50,0
00) 
20yr: $17,850-
35.740 
Cost-
effective
26yr: $19,160-
37,830  
Cost-
effective
Ashish 
A. 
Deshmu
kh, et
al. [47] 
201
4 
USA No 
targeted 
vaccinat
ion for 
HIV- 
Target
d 
vaccinat
ion for
HIV- 
US$500/3-
dose/person;
3% DR;
50% VE;
>20yr 
2013- 
2113 
VE (HR =
0.25) $27,436-
30,867 
ANA 
reduced by 
86-92% 
Cost-
effective
(WTP: 
US$50,0
00) 
Ac
ce
pte
d M
an
us
cri
pt
 
82 
and ≥
27yr 
MSM 
after 
treatme
nt for 
HGAIN 
and ≥
27yr 
MSM 
after 
treatme
nt for
HGAIN 
with 
4vHPV 
protection. 
VE (HR =
0.50): 
$87,240-
169,035 
ANA 
reduced by 
61-69% 
Margina
lly cost-
effective
VE (HR =
0.75): 
$170,975-
524,079 
ANA 
reduced by 
30-34% 
Not 
cost-
effective
Ashish 
A. 
Deshmu
kh, et
al. [46] 
201
5 
USA ≥ 27yr 
MSM 
(HIV+), 
without 
vaccinat
ion after 
tr atme
nt for 
HGAIN
,  
≥ 27yr 
MSM 
(HIV+), 
with 
4vHPV 
after 
treatme
nt for
HGAIN,
US$500/3-
dose/person; 
3% DR; >6-
8yr 
protection. 
2014- 
2114 
Dominance 
(reduction in
treatment cost
and gain in
QALYs) 
ANA 
reduced by 
63%  
Cost-
saving 
(WTP: 
US$50,0
00) 
Ac
ce
pte
d M
an
us
cri
pt
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Allen 
Lin [48] 
201
6 
Engla
nd 
No 
targeted 
vaccinat
ion for 
MSM 
Target 
16-40yr 
MSM 
(HIV 
+/-), 
with 
4vHPV, 
 
£48-
96.5/dose/pe
rson; 3.5%
DR; 64-78%
VE; lifetime
protection; 
80% 
coverage. 
2015- 
2115 
£96.5/dose: 
£32,800 
• GW 
incidence 
reduced by 
15-35% 
within 5yr 
ANA 
reduced by 
40-55% 
reduction 
over 100yr.  
Cost-
effective 
for 
HIV+ 
MSM  
£48/dose: 
£14,000 
Cost-
effective 
for all 
MSM 
(WTP: 
£20,000)
Ac
ce
pte
d M
an
us
cri
pt
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Item 
Heterosexual men 
,
[
]
,
[
] [
]
g
,
[
]
,
[
]
p
g
,
[
]
,
[
]
et
 a
l.[
28
] [
]
,
[
]
,
[
] ,
[
]
[
]
Stud
y 
desig
n 
                          
The 
resear
ch 
questi
on is 
stated 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
85 
The 
econo
mic 
impor
tance 
of the 
resear
ch 
questi
on is 
stated 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
The 
viewp
oint(s
) of 
the 
analy
sis 
are 
clearl
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
86 
y 
stated 
and 
justifi
ed 
The 
ration
ale 
for 
choos
ing 
altern
ative 
progr
amme
s or 
interv
ention
s 
comp
ared 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
87 
is 
stated 
The 
altern
atives 
being 
comp
ared 
are 
clearl
y 
descri
bed 
✓ ✓ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
The 
form 
of 
econo
mic 
evalu
ation 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
88 
used 
is 
stated 
The 
choic
e of 
form 
of 
econo
mic 
evalu
ation 
is 
justifi
ed in 
relati
on to 
the 
questi
ons 
addre
✓ ✓ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
89 
ssed 
Data 
collec
tion 
                          
The 
sourc
e(s) 
of 
effect
ivene
ss 
estim
ates 
used 
are 
stated 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Detail
s of 
the 
✓ NA ✓ ✓ ✓ ✓ ✓ NA NA NA NA NA ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
90 
desig
n and 
result
s of 
effect
ivene
ss 
study 
are 
given 
(if 
based 
on a 
single 
study) 
Detail
s of 
the 
metho
ds of 
synth
NA ✓ NA NA NA ✓ ✓ ✓ ✓ ✓ ✓ ✓ NA 
Ac
ce
pte
d M
an
us
cri
pt
 
91 
esis 
or 
meta-
analy
sis of 
estim
ates 
are 
given 
(if 
based 
on a 
synth
esis 
of a 
numb
er of 
effect
ivene
ss 
studie
Ac
ce
pte
d M
an
us
cri
pt
 
92 
s) 
The 
prima
ry 
outco
me 
meas
ure(s) 
for 
the 
econo
mic 
evalu
ation 
are 
clearl
y 
stated 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Meth
ods to 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
93 
value 
benefi
ts are 
stated 
Detail
s of 
the 
subje
cts 
from 
whom 
valuat
ions 
were 
obtain
ed 
were 
given 
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✓ ✓ ✓ ✓ ✓ 
Produ
ctivit
NA NA NA NA NA NA NA NA NA NA NA NA NA 
Ac
ce
pte
d M
an
us
cri
pt
 
94 
y 
chang
es (if 
includ
ed) 
are 
report
ed 
separ
ately 
The 
releva
nce of 
produ
ctivit
y 
chang
es to 
the 
study 
questi
NA NA NA NA NA NA NA NA NA NA NA NA NA 
Ac
ce
pte
d M
an
us
cri
pt
 
95 
on is 
discus
sed 
Quant
ities 
of 
resour
ce use 
are 
report
ed 
separ
ately 
from 
their 
unit 
costs 
NA NA NA NA NA NA NA NA NA NA NA NA NA 
Meth
ods 
for 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
96 
the 
estim
ation 
of 
quanti
ties 
and 
unit 
costs 
are 
descri
bed 
Curre
ncy 
and 
price 
data 
are 
recor
ded 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
97 
Detail
s of 
curre
ncy 
of 
price 
adjust
ments 
for 
inflati
on or 
curre
ncy 
conve
rsion 
are 
given 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Detail
s of 
any 
✓ ✓ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
98 
model 
used 
are 
given 
The 
choic
e of 
model 
used 
and 
the 
key 
param
eters 
on 
which 
it is 
based 
are 
justifi
✓ ✓ NA ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
99 
ed 
Anal
ysis 
and 
inter
preta
tion 
of 
result
s 
                          
Time 
horiz
on of 
costs 
and 
benefi
ts is 
stated 
✓ ✗ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ 
The ✓ ✓ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
100 
disco
unt 
rate(s
) is 
stated 
The 
choic
e of 
disco
unt 
rate(s
) is 
justifi
ed 
✗ ✗ NA ✗ ✗ ✗ ✓ ✗ ✓ ✗ ✗ ✗ ✗ 
An 
expla
nation 
is 
given 
if 
NA NA NA NA NA NA NA NA NA NA NA NA NA 
Ac
ce
pte
d M
an
us
cri
pt
 
101 
costs 
and 
benefi
ts are 
not 
disco
unted 
Detail
s of 
statist
ical 
tests 
and 
CIs 
are 
given 
for 
stoch
astic 
data 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
102 
The 
appro
ach to 
sensit
ivity 
analy
sis is 
given 
✓ ✓ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
The 
choic
e of 
variab
les 
for 
sensit
ivity 
analy
sis is 
justifi
ed 
✓ NA NA ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
103 
The 
range
s over 
which 
the 
variab
les 
are 
varied 
are 
justifi
ed 
✓ ✗ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Relev
ant 
altern
atives 
are 
comp
ared 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
104 
Incre
menta
l 
analy
sis is 
report
ed 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Major 
outco
mes 
are 
prese
nted 
in a 
disag
gregat
ed as 
well 
as 
aggre
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
105 
gated 
form 
The 
answe
r to 
the 
study 
questi
on is 
given 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Concl
usion
s 
follo
w 
from 
the 
data 
report
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
106 
ed 
Concl
usion
s are 
acco
mpani
ed by 
the 
appro
priate 
cavea
ts 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
✗, 
no; 
✓, 
yes; 
NA, 
not 
applic
Ac
ce
pte
d M
an
us
cri
pt
 
107 
able. 
 
  
Ac
ce
pte
d M
an
us
cri
pt
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Item 
Heterosexual men 
p
,
[
]
[
] y
g
,
[
]
,
[
]
,
[
,
[
]
p
,
[
]
,
[
]
,
[
]
g
,
[
]
,
[
]
,
[
]
,
[
]
Study 
desig
n 
                          
The 
resear
ch 
questi
on is 
stated 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
109 
The 
econo
mic 
impor
tance 
of the 
resear
ch 
questi
on is 
stated 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
The 
viewp
oint(s
) of 
the 
analys
is are 
clearl
y 
✓ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
110 
stated 
and 
justifi
ed 
The 
ration
ale for 
choos
ing 
altern
ative 
progr
amme
s or 
interv
ention
s 
comp
ared 
is 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
111 
stated 
The 
altern
atives 
being 
comp
ared 
are 
clearl
y 
descri
bed 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
The 
form 
of 
econo
mic 
evalu
ation 
used 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
112 
is 
stated 
The 
choic
e of 
form 
of 
econo
mic 
evalu
ation 
is 
justifi
ed in 
relatio
n to 
the 
questi
ons 
addre
✓ NA ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
113 
ssed 
Data 
collec
tion 
                          
The 
sourc
e(s) of 
effecti
venes
s 
estim
ates 
used 
are 
stated 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Detail
s of 
the 
desig
✓ ✗ ✓ NA NA ✓ ✓ ✓ NA NA ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
114 
n and 
result
s of 
effecti
venes
s 
study 
are 
given 
(if 
based 
on a 
single 
study) 
Detail
s of 
the 
metho
ds of 
synth
esis or 
NA NA NA ✓ ✓ NA NA NA ✓ ✓ NA NA NA 
Ac
ce
pte
d M
an
us
cri
pt
 
115 
meta-
analys
is of 
estim
ates 
are 
given 
(if 
based 
on a 
synth
esis of 
a 
numb
er of 
effecti
venes
s 
studie
s) 
Ac
ce
pte
d M
an
us
cri
pt
 
116 
The 
prima
ry 
outco
me 
measu
re(s) 
for 
the 
econo
mic 
evalu
ation 
are 
clearl
y 
stated 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Meth
ods to 
value 
✓ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
117 
benefi
ts are 
stated 
Detail
s of 
the 
subjec
ts 
from 
whom 
valuat
ions 
were 
obtain
ed 
were 
given 
✓ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓ ✗ ✓ ✓ 
Produ
ctivity 
chang
NA NA NA NA NA NA NA NA NA NA NA NA NA 
Ac
ce
pte
d M
an
us
cri
pt
 
118 
es (if 
includ
ed) 
are 
report
ed 
separa
tely 
The 
releva
nce of 
produ
ctivity 
chang
es to 
the 
study 
questi
on is 
discus
NA NA NA NA NA NA NA NA NA NA NA NA NA 
Ac
ce
pte
d M
an
us
cri
pt
 
119 
sed 
Quant
ities 
of 
resour
ce use 
are 
report
ed 
separa
tely 
from 
their 
unit 
costs 
NA NA NA NA NA NA NA NA NA NA NA NA NA 
Meth
ods 
for 
the 
estim
✓ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
120 
ation 
of 
quanti
ties 
and 
unit 
costs 
are 
descri
bed 
Curre
ncy 
and 
price 
data 
are 
record
ed 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Detail
s of 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
121 
curren
cy of 
price 
adjust
ments 
for 
inflati
on or 
curren
cy 
conve
rsion 
are 
given 
Detail
s of 
any 
model 
used 
are 
✓ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
122 
given 
The 
choic
e of 
model 
used 
and 
the 
key 
param
eters 
on 
which 
it is 
based 
are 
justifi
ed 
✓ NA ✓ ✓ ✓ ✓ NA ✓ ✓ ✓ NA ✓ ✓ 
Analy
sis 
                          
Ac
ce
pte
d M
an
us
cri
pt
 
123 
and 
inter
preta
tion 
of 
result
s 
Time 
horizo
n of 
costs 
and 
benefi
ts is 
stated 
✓ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
The 
disco
unt 
rate(s) 
is 
✓ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
124 
stated 
The 
choic
e of 
disco
unt 
rate(s) 
is 
justifi
ed 
✗ NA ✓ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ 
An 
expla
nation 
is 
given 
if 
costs 
and 
benefi
ts are 
NA NA NA NA NA NA NA NA NA NA NA NA NA 
Ac
ce
pte
d M
an
us
cri
pt
 
125 
not 
disco
unted 
Detail
s of 
statist
ical 
tests 
and 
CIs 
are 
given 
for 
stocha
stic 
data 
✓ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
The 
appro
ach to 
sensiti
✓ NA ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
126 
vity 
analys
is is 
given 
The 
choic
e of 
variab
les for 
sensiti
vity 
analys
is is 
justifi
ed 
✓ NA ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ NA ✓ ✓ 
The 
range
s over 
which 
the 
✓ NA ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ NA ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
127 
variab
les are 
varied 
are 
justifi
ed 
Relev
ant 
altern
atives 
are 
comp
ared 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Incre
menta
l 
analys
is is 
report
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
128 
ed 
Major 
outco
mes 
are 
prese
nted 
in a 
disag
gregat
ed as 
well 
as 
aggre
gated 
form 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
The 
answe
r to 
the 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
129 
study 
questi
on is 
given 
Concl
usions 
follo
w 
from 
the 
data 
report
ed 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Concl
usions 
are 
acco
mpani
ed by 
the 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Ac
ce
pte
d M
an
us
cri
pt
 
130 
appro
priate 
caveat
s 
✗, no; 
✓, 
yes; 
NA, 
not 
applic
able. 
 
